carbidopa has been researched along with Disease Exacerbation in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (14.29) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, MJ; Okun, MS | 1 |
| Carroll, DG; Halli-Tierney, AD; Luker, J | 1 |
| Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijkgraaf, MGW; Lang, AE; Munts, AG; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM | 1 |
| Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L | 1 |
| Alexiou, A; Psiha, M; Vlamos, P | 1 |
| Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y | 1 |
| Bloem, BR; de Bie, RM; de Haan, RJ; Deuschl, G; Dijkgraaf, M; Lang, AE; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CV | 1 |
| Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M | 1 |
| Silver, DE | 1 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Hazan, D; Siegert, S; Szyper-Kravitz, M | 1 |
| Cheng, H; Cox, ME; Fazli, L; Fukumoto, T; Ghaidi, F; Gleave, ME; Plaa, N; Rennie, PS; Wafa, LA | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Cheng, H; Fazli, L; Gleave, ME; Lamoureux, F; Rennie, PS; Thomas, C; Wafa, LA | 1 |
| Tarsy, D | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 2 |
| Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A | 1 |
| Jung, SK | 1 |
| Fahn, S; Kieburtz, K; Lang, A; Marek, K; Oakes, D; Olanow, CW; Rudolph, A; Shoulson, I; Tanner, C | 1 |
| Fahn, S | 1 |
| Iyer, SS; Morgan, JC; Sethi, KD | 1 |
| Aquilonius, SM; Hansson, LE; Johansson, K; Nilsson, D; Nyström, C; Paalzow, L | 1 |
| Stacy, M | 1 |
| DeLong, MR; Rye, DB | 1 |
| Scheife, RT | 1 |
| Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW | 1 |
3 review(s) available for carbidopa and Disease Exacerbation
| Article | Year |
|---|---|
Diagnosis and Treatment of Parkinson Disease: A Review.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis | 2020 |
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life.
Topics: Accidental Falls; Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Disease Progression; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Patient Care Planning; Practice Guidelines as Topic; Quality of Life; Safety Management | 2007 |
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
Topics: Antiparkinson Agents; Brain; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
6 trial(s) available for carbidopa and Disease Exacerbation
| Article | Year |
|---|---|
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time-to-Treatment | 2019 |
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Netherlands; Parkinson Disease; Quality of Life; Time-to-Treatment | 2015 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
Levodopa and the progression of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed, Single-Photon | 2004 |
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Disease Progression; Duodenum; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies; Time Factors; Treatment Outcome; Videotape Recording | 1998 |
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome | 2000 |
19 other study(ies) available for carbidopa and Disease Exacerbation
| Article | Year |
|---|---|
Parkinson Disease.
Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities | 2020 |
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Towards an expert system for accurate diagnosis and progress monitoring of Parkinson's disease.
Topics: Algorithms; Antiparkinson Agents; Biomarkers; Carbidopa; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Expert Systems; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity | 2015 |
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis.
Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders | 2015 |
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up.
Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment.
Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss | 2011 |
Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression.
Topics: Animals; Apoptosis; Carbidopa; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dopa Decarboxylase; Gene Expression Regulation, Neoplastic; Male; Mice; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents; Apoptosis; Carbidopa; Cell Line, Tumor; Cell Survival; Disease Progression; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Reversal of parkinsonism following liver transplantation.
Topics: Acute Disease; Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Remission Induction; Treatment Outcome; Tremor | 2003 |
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording | 2004 |
A young onset Parkinson's patient: a case study.
Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome | 2004 |
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar.
Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone | 1999 |
Amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy.
Topics: Anticonvulsants; Carbidopa; Disease Progression; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Treatment Outcome | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |
The effect of pregnancy in Parkinson's disease.
Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life | 2000 |